Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient ASHBURN, Va., ...